Saturday 17 October 2026
Export HSCS’s income statement to Excel — free account
HeartSciences Inc.
HSCS Healthcare Medical Devices
HeartSciences Inc.’s revenue for fiscal 2026 (year ended April 2026) was $4,300.00, down 2.27% from fiscal 2025. In the quarter to July 2026, revenue fell 46.2%, EPS grew 45.6% and free cash flow grew 18.2%, each against the same quarter a year earlier.
3.02
0.16
−5.03%
Follow HSCS
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
379.06 | — | — | 370.33 | |
P/FCF ratio |
0.00 | — | — | 0.00 | |
P/Operating CF |
(6.06) | — | — | (3.63) | |
P/B ratio |
0.00 | — | — | 2.03 | |
Price to Tangible BV |
0.00 | — | — | 3.32 | |
EV/Sales |
409.47 | — | — | 298.21 | |
EV/EBITDA |
0.00 | — | — | 0.00 | |
EV/Operating CF |
(1.27) | — | — | (0.91) | |
EV/FCF |
(1.21) | — | — | (0.91) | |
Quick Ratio |
0.01 | 0.34 | 0.80 | 1.25 | |
Current Ratio |
0.14 | 0.53 | 1.19 | 2.42 | |
Net Debt/EBITDA |
0.01 | 0.69 | 1.59 | 1.10 | |
Debt/Assets |
0.00% | 0.00% | 5.58% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.16 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.42 | 0.61 | 0.74 | 0.99 | |
Capex/Depreciation |
(2.07) | 0.00 | (0.51) | (0.05) | |
Interest Coverage |
(12.49) | (11.11) | (31.36) | (7.42) | |
Research and Development Expense of Revenue |
43,171.43% | 0.00% | 0.00% | 30,291.67% | |
Selling, General and Administrative Expense of Revenue |
96,847.62% | 0.00% | 0.00% | 56,158.33% | |
Intangible Assets out of Total Assets |
0.44 | 0.31 | 0.22 | 0.27 | |
Share Based Compensation of Revenue |
35,185.71% | 0.00% | 0.00% | 18,200.00% | |
Graham Net Nets |
(0.62) | — | — | 0.23 | |
Graham Number |
6.34 | — | — | 0.00 | |
Earnings Yield |
(147.71%) | — | — | (225.57%) | |
Free Cash Flow Yield |
(88.97%) | — | — | (88.93%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.36) | (0.64) | (0.46) | (0.84) | |
Capex per Share |
(0.08) | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.44) | (0.64) | (0.47) | (0.85) | |
Cash per Share |
0.01 | 0.63 | 1.07 | 0.70 | |
Shareholders Equity per Share |
(0.55) | 0.09 | 0.84 | 1.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.55) | 0.09 | 0.84 | 1.50 | |
Free Cash Flow |
(1.60) | (1.68) | (1.49) | (2.35) | |
Working Capital |
(4.82) | (2.28) | 0.83 | 2.23 | |
Capital Expenditures |
(0.28) | 0.00 | (0.03) | (0.02) | |
Net Current Asset Value |
(4.96) | (2.45) | 0.20 | 1.98 | |
EV/EBIT |
0.00 | — | — | 0.00 | |
Capex to Sales |
133.38 | 0.00 | 0.00 | 6.58 | |
Price to Operating Income |
0.00 | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
0.65 | 0.32 | 0.41 | 0.30 | |
Average Inventory |
0.53 | 0.65 | 0.65 | 0.66 | |
Average Assets |
5.09 | 4.74 | 6.63 | 6.89 | |
Average Common Equity |
0.55 | 0.22 | 2.22 | 4.10 |
Columns are period end dates · fundamentals updated 1 Oct 2026